Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in…
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.13, read 2026-11-03
Ethical passes the values gate
Price36.28 USD
Fair value53.00
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-21Read Markdown34.77+4.3% to today Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation35.38+2.5% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-09-02Read Markdown35.97+0.9% to today Markup gives way to Markdown after a 10% slide in 4 weeks
2026-08-02Read Markup40.01-9.3% to today Accumulation gives way to Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Indivior Pharmaceuticals, Inc. holds its Markdown at $36.28. The statistical read favours the sellers, held for 965 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 965 days
Price at the screen
$36.28
Valuation
10.16 trailing · 8.05 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.13
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.23%
Below 33%
Interest-bearing debt is just 29.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
37.30%
Below 49%
Money owed to the company is 37.3% of assets, under the 49% limit.
Pass
Revenue purity
1.78%
Below 5%
Only 1.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Indivior Pharmaceuticals, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 29%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when INDV's ethical verdict changes
Today INDV passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 32% discount to our $53.00 fair value, 13.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 31.5% discount to the base estimate.
Where our models see it going: fair-value estimate $53.00, with a range of $53.00 to $72.56, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Addiction treatment at a bargain price
Opioid dependence keeps rising, yet Indivior sells the main buprenorphine medicines that help patients step away from heroin and painkillers. The business is expanding revenue 19 percent a year, turning 20 percent of sales into profit, and trades on a forward multiple of just 9.8 times earnings. Our fair-value estimate sits at 59 dollars against the current 40.54, giving a 46 percent margin of safety while the ethical screen flags the work as clearly useful.
Six analysts see a median target of 50 dollars, so the shares already look cheap on simple numbers. Unknown competitive defences and heavy reliance on one drug family keep the opportunity rating at none, which stops any stronger call. Currency moves, regulatory shifts on addiction medicines, and possible new entrants remain real threats to those margins.
The low multiple may simply reflect those gaps rather than a mispriced winner. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INDV trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$36.28+4.3%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-10-29Markdown$34.77+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$34.77+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$34.77+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$34.77+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$34.77+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$34.77+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$34.77+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$34.77+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown · changed$34.77-3.0%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
